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Conclusion: Together, our ﬁndings indicate dynamic changes
to macrophage and monocytes populations in VL patients over the
course of drug treatment, and suggest that the functions of these
cells may change at different stages of disease. We found upregu-
lation of some markers for monocyte deactivation.
http://dx.doi.org/10.1016/j.ijid.2016.02.815
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Background: Laboratory tests which can be produced in a
reproducible and scalable manner are much needed to identify
visceral leishmaniasis (VL) infection and fulﬁll the goals of the elim-
ination campaign. Whole blood interferon gamma (IFN-) release
assay (IGRAs) is an in vitro immune test that has recently been
developed as an alternative to the Leishmanin skin test (LST) for
identiﬁcation of individuals exposed to L.donovani infection but
without disease. Requirement of 3 ml of blood preclude this test
widely acceptable for larger community based studies. This study
aimed at evaluating the performance of microplate based IGRA
using 300l blood (direct blood as well as 1:1RPMI diluted blood)
with conventional IGRA (3ml blood) to establish this assay as an
epidemiological tool for marker of infection.
Methods & Materials: We employed conventional IGRA and
microplate based IGRA with direct as well as diluted venous blood
using soluble leishmania antigen (SLA) on patients with active vis-
ceral leishmaniasis (VL, n =32), patients with cured VL (n=20),
endemic Healthy Controls (EHC, n =21) and healthy control sub-
jects living in non-endemic area (NEHC, n=12). IFN levels in
culture supernatants were measured by ELISA and kappa statistics
was used to access the concordance between test assay formats.
Results: The whole blood cells of both active VL and cured
VL produced signiﬁcantly level of IFN- in both format of IGRA.
Positive correlations were found with active VL blood in IFN- pro-
ductionbetween3mlvs600l, 3mlvs300l, and600l vs 300l,
whilewith curedVLblood itwasmoderatewith3ml vs 600l; 3ml
vs 300l. No signiﬁcant difference in the overall IFN- response by
both assay formatswasdetected, and agreement between testswas
signiﬁcant.
Conclusion: We demonstrate a reliable and scalable process
similar in sensitivity to conventional IGRA, but with the advantage
of 10 times less venous blood requirement and higher through-put.
Development of microplate based IGRA format will be useful tool
for providing the means to more efﬁcient screening in large scale
immunological and epidemiological studies and ﬁll an unmet need
in the VL elimination campaign on the Indian sub-continent.
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Background:Miltefosine is an oral antileishmanial drug. Recent
reports indicate a signiﬁcant decline in its efﬁcacy and high relapse
rate in visceral leishmaniasis (VL) and post kala-azar dermal leish-
maniasis (PKDL). Miltefosine susceptibility of relapse case isolates
were >3 fold lower compared to pre treatment isolates.
Methods & Materials: To understand mechanism responsible
for miltefosine unresponsiveness, we determined (i) the sequence
of LdMTandLdRosgenes implicated inmiltefosine translocation (ii)
miltefosine accumulation and reactive oxygen species (ROS) toler-
ance and (iii) transcriptomeproﬁle in clinical isolates of Leishmania
donovani obtained from VL and PKDL patient at pre treatment
and clinically relapsed stages as well as miltefosine resistant para-
site(LdM30).
Results: LdMT gene sequencing revealed the previously
reported single-nucleotide polymorphism, C1259→A resulting in
substitution of Thr 420→Asn and a novel SNP T527-A result-
ing in substitution of Val176-Asp resistant parasites. L. donovani
parasites from VL and PKDL patients relapsed after miltefosine
treatment exhibited signiﬁcantly lower accumulation of miltefo-
sine compared with wild type parasites. Miltefosine induced ROS
levels were signiﬁcantly low (p<0.05) in macrophages infected
with LdM30 and parasites from relapse cases compared to wild
type parasites, indicating better tolerance for oxidative stress in
unresponsive clinical isolates. Transcriptome proﬁling revealed
that several genes involved in antioxidant defense mechanism
(TRYP, Cyt b5 Red, TSH),metabolic process (Lipase precursor, PGM-
PUT), transporters (VPTM,MDRP), cell component and cell motility
(SMP2, NUP155, CYP) are preferentially expressed in LdM30 and
relapsedcaseparasites thanwild typeL. donovaniparasites. Several
othergenesmainly transporters likeABCF2, aminoacid transporter,
surface acylated putative protein, APH and mitochondrial precur-
sor peptide, chaperon TCP20, clathrin coated assembly protein,
C5 sterol desaturase, autophagy protein ATG10 were preferen-
tially expressed in wild type parasite compared to relapse case and
LdM30 parasites.
Conclusion: The present study provides the understanding of
parasitic factors and pathways responsible for miltefosine unre-
sponsiveness in VL and PKDL. Decreased miltefosine susceptibility
and increasing relapse rate in VL and PKDL patients indicate the
declining efﬁcacy of monotherapy with miltefosine and warrants
the need of introducing alternate drugs/ combination therapy with
miltefosine.
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